SCHEMBL23748295

SCHEMBL23748295

C=CCCc1cc(F)ccc1C(Cl)c1ccccn1

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
F2RL1 P55085 3/20 0.33
ALDH1A1 P00352 1/20 0.33
ALOX15 P16050 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
HSD17B10 Q99714 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CHRM2 P08172 1/20 0.33
CHRM4 P08173 1/20 0.33
CHRM5 P08912 1/20 0.33
CHRM1 P11229 1/20 0.33
CHRM3 P20309 1/20 0.33
SQOR Q9Y6N5 1/20 0.32
CD74 P04233 1/20 0.32
MIF P14174 1/20 0.32
GRM5 P41594 1/20 0.30
DPP4 P27487 1/20 0.30
DPP8 Q6V1X1 1/20 0.30
DPP9 Q86TI2 1/20 0.30
DPP7 Q9UHL4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23748146 0.86 SQOR (0.30) SQORDPP4
SCHEMBL23748219 0.85 F2RL1 (0.43) F2RL1ALDH1A1ALOX15NPSR1HSD17B10
SCHEMBL23748227 0.84 SLC6A2 (0.33) CHRM2
SCHEMBL23748242 0.78 L3MBTL1 (0.41) ALDH1A1ALOX15NPSR1HSD17B10L3MBTL1
SCHEMBL23748150 0.74 MAPT (0.39) SQOR
SCHEMBL23748215 0.73 ADRA2B (0.40) ALDH1A1HSD17B10
SCHEMBL23748292 0.71 HRH1 (0.30)
SCHEMBL23748156 0.70 MAPT (0.36) ALDH1A1HSD17B10L3MBTL1CHRM5SQOR
SCHEMBL23748161 0.69 MAPT (0.43) ALDH1A1
SCHEMBL23748244 0.69 TSHR (0.39) ALDH1A1HSD17B10L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 US disclosed
US-11312727-B1 Macrocyclic flu endonuclease inhibitors Janssen Biopharma, Inc. (US) 2022-04-26 US disclosed
EP-3864020-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS Janssen BioPharma, Inc. (US) 2021-08-18 EP disclosed
CN-113195502-A Macrocyclic influenza endonuclease inhibitors 詹森生物制药有限公司 2021-07-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS ACE, PNP, FEN1 F2RL1 654/4885ALDH1A1 2073/4885ALOX15 2194/4885
US-11312727-B1 Macrocyclic flu endonuclease inhibitors ACE, FEN1, PNP F2RL1 592/4885ALDH1A1 1487/4885ALOX15 1563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.